ResearcherQueen Mary University of LondonActive in the last 2 years
Christine Hughes
Matched on ORCID iD 0000-0002-4477-5305. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 3 papers
Papers 6
- AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. Co-author DOI 10.1038/s41598-025-87337-5↗
- Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
- Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer. Co-author DOI 10.3389/fonc.2025.1672385↗
- Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study. Co-author DOI 10.3390/cancers15010280↗
- Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
- Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Co-author DOI 10.1038/s41467-020-18636-w↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hemant Mahendrakumar Kocher · 6 shared papers, 2020–2025 · strength 1.20
- Paper Plasma vascular endothelial growth factor levels are a potential therapy-response biomarker for pancreatic cancer. DOI 10.3389/fonc.2025.1672385↗
- Paper AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. DOI 10.1038/s41598-025-87337-5↗
- Paper Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced panc… DOI 10.1186/s12885-024-13333-z↗
- Claude Chelala · 3 shared papers, 2022–2025 · strength 0.59
- Paper AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. DOI 10.1038/s41598-025-87337-5↗
- Paper Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced panc… DOI 10.1186/s12885-024-13333-z↗
- Paper Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospectiv… DOI 10.3390/cancers15010280↗
- Oleg B. Blyuss · 1 shared paper, 2025 · strength 0.42
- Mohamed Zardab · 2 shared papers, 2022–2025 · strength 0.40
- David J. Propper · 2 shared papers, 2020–2025 · strength 0.28
- Paper Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced panc… DOI 10.1186/s12885-024-13333-z↗
- Paper Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. DOI 10.1038/s41467-020-18636-w↗
- Fieke E. M. Froeling · 2 shared papers, 2020–2025 · strength 0.28
- Paper Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced panc… DOI 10.1186/s12885-024-13333-z↗
- Paper Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. DOI 10.1038/s41467-020-18636-w↗
- Debashis Sarker · 2 shared papers, 2020–2025 · strength 0.28
- Paper Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced panc… DOI 10.1186/s12885-024-13333-z↗
- Paper Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. DOI 10.1038/s41467-020-18636-w↗
- Richard Philip Grose · 1 shared paper, 2025 · strength 0.26
- Barts Pancreas Tissue Bank · 1 shared paper, 2025 · strength 0.26
- Michelle Rodriques Goulart · 2 shared papers, 2020–2021 · strength 0.19
- Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19
- David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.19
- Mairead Geraldine McNamara · 1 shared paper, 2025 · strength 0.19
- Pippa G. Corrie · 1 shared paper, 2025 · strength 0.19
- Vickna Balarajah · 1 shared paper, 2022 · strength 0.14
- Abu Z M Dayem Ullah · 1 shared paper, 2022 · strength 0.14
- Jennifer Watt · 1 shared paper, 2021 · strength 0.11
- Somnath Mukherjee · 1 shared paper, 2021 · strength 0.11
- Chris N Hurt · 1 shared paper, 2021 · strength 0.11
- Rita Teresa Lawlor · 1 shared paper, 2021 · strength 0.11
- Tatjana Crnogorac‐Jurcevic · 1 shared paper, 2021 · strength 0.11
- Aldo Scarpa Scarpa · 1 shared paper, 2021 · strength 0.11
- Paola Allavena · 1 shared paper, 2021 · strength 0.11
- Roberto Salvia · 1 shared paper, 2021 · strength 0.11
- Sarah Slater · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.